PharmaShots | Incisive News in 3 Shots

Subscribe Now

ROS1-Positive

Turning Point's Repotrectinib Receives the US FDA's Breakthrough Therapy Designation for the Treatment of ROS1-Positive Metastatic Non-Small Cell Lung Cancer

Turning Point's Repotrectinib Receives the US FDA's Breakthrough Therapy Designation for the Treatment of ROS1-Positive Metastatic...

December 8, 2020

Roche's Rozlytrek Receives EC's Conditional Marketing Authorization for NTRK Fusion-Positive Solid Tumors and ROS1-Positive Advanced NSCLC

Roche's Rozlytrek Receives EC's Conditional Marketing Authorization for NTRK Fusion-Positive Solid Tumors and ROS1-Positive Advanc...

August 3, 2020

Roche's Rozlytrek (entrectinib) Receives the US FDA Approval for ROS1-Positive Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors

Roche's Rozlytrek (entrectinib) Receives the US FDA Approval for ROS1-Positive Metastatic Non-Small Cell Lung Cancer and NTRK Gene...

August 16, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us